Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
26.72
-0.49 (-1.80%)
Streaming Delayed Price
Updated: 10:49 AM EDT, May 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals.
↗
November 25, 2024
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.
Via
Chartmill
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
↗
November 18, 2024
NASDAQ:GMAB, a growth stock which is not overvalued.
Via
Chartmill
A Closer Look at 10 Analyst Recommendations For Genmab
↗
November 08, 2024
Via
Benzinga
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Genmab A/S
Via
Business Wire
Preview: Genmab's Earnings
↗
November 05, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
↗
October 30, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
12 Analysts Have This To Say About Genmab
↗
October 16, 2024
Via
Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
↗
October 09, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
↗
October 08, 2024
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
NASDAQ:GMAB, a growth stock which is not overvalued.
↗
October 07, 2024
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via
Chartmill
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
↗
October 29, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
↗
October 28, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive.
Via
Chartmill
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
September 23, 2024
Via
Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
↗
September 17, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals.
Via
Chartmill
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
↗
September 16, 2024
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From
Genmab A/S
Via
Business Wire
Expert Ratings For Genmab
↗
September 09, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
↗
September 03, 2024
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
↗
August 26, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing.
Via
Chartmill
Decoding 10 Analyst Evaluations For Genmab
↗
August 20, 2024
Via
Benzinga
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
Business Wire
Genmab Announces Changes to its Executive Committee
August 16, 2024
From
Genmab A/S
Via
Business Wire
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
↗
August 05, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
What 8 Analyst Ratings Have To Say About Genmab
↗
August 01, 2024
Via
Benzinga
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
↗
August 13, 2024
Via
Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
↗
August 05, 2024
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...
Via
Benzinga
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
↗
August 05, 2024
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via
Chartmill
What 8 Analyst Ratings Have To Say About Genmab
↗
July 15, 2024
Via
Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
↗
July 15, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
